« Back
Home /
Recombinant SARS-CoV-2 S1 Subunit Protein RBD, R346K/E484K/N501Y mutant

Recombinant SARS-CoV-2 S1 Subunit Protein RBD, R346K/E484K/N501Y mutant

Manufacturer	Raybiotech
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Specific against	other
Format	Liquid
Applications	WB, IP, ELISA, Dot
Amount	500 ug
Item no.	230-30213-500
Conjugate/Tag	His
eClass 6.1	34160400
eClass 9.0	42020190
Available
Purity	>95% - SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Application Information	Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Storage/Stability	Upon arrival, the protein may be stored for 2 weeks at 4 °C. For long term storage, it is recommended to store at -20 °C or -80 °C in appropriate aliquots. Avoid repeated freeze-thaw cycles.
Formulation	Supplied as a 0.2 um filtered solution in PBS (pH 7.4)
Expressed Region	Arg319-Phe541. R346K/E484K/N501Y mutant: amino acid Arg (R) at 346 position was mutated to Lys (K), Glu (E) at 484 position was mutated to Lys (K), Asn (N) at 501 position was mutated to Tyr (Y).
Protein Name & Synonyms	Spike protein, S Protein, S1 Subunit, Host Cell Receptor Binding Domain (RBD)
Expression System	Human embryonic kidney 293 (HEK293) cells
Purification	His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Concentration (lot specific)	Lot specific (see the label on the vial), determined by BCA protein assay
Endotoxin Level	< 0.5 EU per µg of the protein as determined by the LAL method
Conjugation/Tag Notes	C-terminal his-tag
Molecular Weight (kDa)	Recombinant protein product has a calculated molecular mass of ∼25 kDa. Due to the abundant glycosylation, it migrates as approximately ∼30 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. After deglycosylation under native and denature conditions, the protein presented as one reduced ∼25 kDa band.
SDS-PAGE Image	Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: Protein standard ladder (kDa). Lane 2: Untreated protein Lane 3: Treated protein with deglycosylation enzymes under native conditions. Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.
Shipping	Ice packs
Custom Labeling Request	We can custom label this protein with biotin or fluorescent dyes (choose from violet, blue, green or red). Request now.
Binding Function	Product binding ability was measured by ELISA. The immobilized recombinant human ACE2 protein (Catalog #230-30165, coated at 0.5 ug/ml, 100 ul/well) was incubated with the serial diluted SARS CoV-2 S1 RBD R346K/E484K/N501Y mutant protein (Catalog #230-30213). The bound mutant protein was detected by mouse anti-S1 RBD monoclonal antibody using ELISA. The calculated EC50 is 39.48 ng/ml.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 500 ug

available

Delivery expected until 8/2/2024